Free Trial
→ Kamala’s final humiliation (From Porter & Company) (Ad)

Onconetix Q1 2023 Earnings Report

$0.54 +0.01 (+1.89%)
As of 01/21/2025 04:00 PM Eastern
Earnings History

Onconetix EPS Results

Actual EPS
-$7.20
Consensus EPS
-$8.40
Beat/Miss
Beat by +$1.20
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Q1 2023
Date
5/12/2023
Time
N/A

Conference Call Resources

Onconetix Earnings Headlines

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
December 12, 2024 | globenewswire.com
Onconetix files to sell 10.59M shares of common stock for holders
November 1, 2024 | markets.businessinsider.com
Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
January 22, 2025 | Timothy Sykes (Ad)
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
October 3, 2024 | globenewswire.com
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
October 3, 2024 | globenewswire.com
What's Going On With Onconetix Shares Friday?
September 28, 2024 | msn.com
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles